Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Breast cancer in adolescents and young adults.

Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A.

Pediatr Blood Cancer. 2018 Aug 28:e27397. doi: 10.1002/pbc.27397. [Epub ahead of print] Review.

PMID:
30156052
2.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Aug 23. pii: theoncologist.2017-0498. doi: 10.1634/theoncologist.2017-0498. [Epub ahead of print]

PMID:
30139837
3.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.

Ann Oncol. 2018 Aug 15. doi: 10.1093/annonc/mdy257. [Epub ahead of print]

PMID:
30124753
4.

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.

Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0085. doi: 10.1634/theoncologist.2018-0085. [Epub ahead of print]

PMID:
30120166
5.

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC.

Mol Cell. 2018 Aug 16;71(4):606-620.e7. doi: 10.1016/j.molcel.2018.07.030.

PMID:
30118680
6.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.

N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

PMID:
30110579
7.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Jul 10. pii: S1526-8209(18)30009-0. doi: 10.1016/j.clbc.2018.07.008. [Epub ahead of print]

PMID:
30077429
8.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Oct;195:28-35. doi: 10.1016/j.clim.2018.06.008. Epub 2018 Jul 17.

PMID:
30025819
9.

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.

Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT.

Breast Cancer Res Treat. 2018 Jun 18. doi: 10.1007/s10549-018-4853-4. [Epub ahead of print]

PMID:
29915946
10.

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.

Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK.

Cancer Med. 2018 Jun;7(6):2718-2726. doi: 10.1002/cam4.1519. Epub 2018 May 7.

11.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

PMID:
29574039
12.

Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.

Chambers MS, Rugo HS, Litton JK, Meiller TF.

J Am Dent Assoc. 2018 Apr;149(4):291-298. doi: 10.1016/j.adaj.2017.10.024. Epub 2018 Feb 10.

PMID:
29439772
13.

Characterization of bone only metastasis patients with respect to tumor subtypes.

Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN.

NPJ Breast Cancer. 2018 Jan 25;4:2. doi: 10.1038/s41523-018-0054-x. eCollection 2018.

14.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

15.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

PMID:
29180466
16.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

PMID:
29093017
17.

BRCA mutations in women with inflammatory breast cancer.

Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK.

Cancer. 2018 Feb 1;124(3):466-474. doi: 10.1002/cncr.31069. Epub 2017 Oct 17.

PMID:
29044548
18.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT.

Ann Oncol. 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

PMID:
28961844
19.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.

J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

20.

Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.

Parkes A, Arun BK, Litton JK.

Oncologist. 2017 Jun;22(6):655-666. doi: 10.1634/theoncologist.2016-0430. Epub 2017 May 3. Review.

21.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

22.

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK.

Lancet Oncol. 2017 May;18(5):654-662. doi: 10.1016/S1470-2045(17)30109-2. Epub 2017 Mar 15.

PMID:
28314691
23.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.

Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S.

J Natl Compr Canc Netw. 2017 Jan;15(1):9-20.

PMID:
28040716
24.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
25.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

26.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

27.

Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.

Breast Cancer Res Treat. 2016 Aug;159(1):201. No abstract available.

PMID:
27464794
28.

Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.

Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.

Oncologist. 2016 Jul;21(7):869-74. doi: 10.1634/theoncologist.2015-0354. Epub 2016 Jun 15.

29.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

30.

Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing.

Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK.

Front Genet. 2016 Apr 27;7:71. doi: 10.3389/fgene.2016.00071. eCollection 2016.

31.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

32.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S.

J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

PMID:
26850485
33.

Rates of BRCA1/2 mutation testing among young survivors of breast cancer.

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.

Breast Cancer Res Treat. 2016 Jan;155(1):165-73. doi: 10.1007/s10549-015-3658-y. Epub 2015 Dec 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):201.

34.

Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.

Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA.

Ann Surg Oncol. 2016 Mar;23(3):749-56. doi: 10.1245/s10434-015-4921-5. Epub 2015 Oct 28.

PMID:
26511263
35.

High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.

Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.

Cancer. 2015 Oct 1;121(19):3422-7. doi: 10.1002/cncr.29572. Epub 2015 Aug 17.

36.

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.

Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK.

J Cancer. 2015 May 23;6(7):610-5. doi: 10.7150/jca.11710. eCollection 2015.

37.

Reply to BRCA2-associated pancreatic cancer and current screening guidelines.

Litton JK, Lee JH, Arun BK.

Cancer. 2015 Sep 1;121(17):3047. doi: 10.1002/cncr.29446. Epub 2015 May 27. No abstract available.

38.

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT.

Oncotarget. 2015 May 30;6(15):12890-908. Review.

39.

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.

Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.

40.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F.

Clin Breast Cancer. 2015 Oct;15(5):325-31. doi: 10.1016/j.clbc.2015.03.004. Epub 2015 Mar 24.

41.

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.

Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT.

J Cancer. 2015 Jan 22;6(4):310-8. doi: 10.7150/jca.10580. eCollection 2015.

42.

Outcomes of children exposed in utero to chemotherapy for breast cancer.

Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK.

Breast Cancer Res. 2014 Dec 30;16(6):500. doi: 10.1186/s13058-014-0500-0.

43.

Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM.

Clin Breast Cancer. 2015 Apr;15(2):153-60. doi: 10.1016/j.clbc.2014.09.006. Epub 2014 Oct 2.

PMID:
25454687
44.

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.

Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.

Cancer. 2015 Jan 15;121(2):269-75. doi: 10.1002/cncr.29041. Epub 2014 Sep 15. Erratum in: Cancer. 2015 Jul 15;121(14):2474-5.

45.

Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.

Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK.

Oncologist. 2014 Aug;19(8):797-804. doi: 10.1634/theoncologist.2014-0057. Epub 2014 Jun 20.

46.

Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.

Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK.

Ann Surg Oncol. 2014 Oct;21(11):3466-72. doi: 10.1245/s10434-014-3747-x. Epub 2014 May 6.

47.

PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.

48.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F.

Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24.

49.

Effect of age and race on quality of life in young breast cancer survivors.

Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN.

Clin Breast Cancer. 2014 Apr;14(2):e21-31. doi: 10.1016/j.clbc.2013.10.003. Epub 2013 Oct 25. Review.

50.

Reply to D. Crivellari et al.

Theriault RL, Litton JK.

J Clin Oncol. 2014 Jan 20;32(3):256-7. doi: 10.1200/JCO.2013.53.1020. Epub 2013 Dec 2. No abstract available.

PMID:
24297948

Supplemental Content

Loading ...
Support Center